CANTEL MEDICAL CORP. (NYSE:CMD) Files An 8-K Submission of Matters to a Vote of Security Holders

0

CANTEL MEDICAL CORP. (NYSE:CMD) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

At the 2017 Annual Meeting, held on January 3, 2018, five proposals were voted on by the Company’s stockholders.The proposals are described in detail in the Company’s definitive proxy statement filed on November 28, 2017 (the “Proxy Statement”) in connection with the 2017 Annual Meeting and summarized below.

A final voting report was produced by Broadridge Financial Solutions,Inc., the independent inspector of election for the 2017 Annual Meeting, certifying the following results on the five proposals:

Proposal 1 The stockholders elected all ten director nominees to serve as members of the Company’s board of directors until the Company’s 2018 Annual Meeting of Stockholders.

Name

For

Withheld

Abstain

Broker

Non-Votes

Alan R. Batkin

36,775,973

744,667

7,468

2,244,375

Ann E. Berman

37,321,222

199,726

7,160

2,244,375

Charles M. Diker

36,841,392

671,682

15,034

2,244,375

Mark N. Diker

37,026,153

493,746

8,209

2,244,375

Anthony B. Evnin

37,151,885

261,417

114,806

2,244,375

Laura L. Forese

37,312,092

209,227

6,789

2,244,375

George L. Fotiades

37,304,318

216,105

7,685

2,244,375

Jorgen B. Hansen

37,021,850

490,810

15,448

2,244,375

Ronnie Myers

37,208,250

209,946

109,912

2,244,375

Peter J. Pronovost

37,284,247

192,420

51,441

2,244,375

Proposal 2 The stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers.

For

Against

Abstain

Broker

Non-Votes

36,679,402

832,016

16,690

2,244,375

Proposal 3 The stockholders approved, on an advisory basis, the frequency of future advisory votes on the compensation of the Company’s Named Executive Officers.

One Year

Two Years

Three Years

Abstain

Broker

Non-Votes

31,846,902

32,001

5,630,874

18,331

2,244,375

Proposal 4 The stockholders approved the amendment of the Company's By-Laws to designate the Delaware Court of Chancery as the exclusive forum for certain legal actions.

For

Against

Abstain

Broker

Non-Votes

22,510,534

15,002,903

14,671

2,244,375

Proposal 5The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending July31, 2018.

For

Against

Abstain

39,496,965

268,737

6,781

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

3.1 Cantel Medical Corp. By-Laws, as amended on January 3, 2018.
3.2 Cantel Medical Corp. By-Laws, as amended on January 3, 2018, marked to show the new amendments.


CANTEL MEDICAL CORP Exhibit
EX-3.1 2 exhibit-cantelbyxlaws.htm EXHIBIT 3.1 Exhibit Exhibit 3.1    CANTEL MEDICAL CORP.    BY-LAWS(As amended through January 3,…
To view the full exhibit click here

About CANTEL MEDICAL CORP. (NYSE:CMD)

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies. The Company’s Water Purification and Filtration segment includes water purification equipment and services, filtration and separation products, and disinfectant, sterilization and decontamination products and services. Its Healthcare Disposables segment includes single-use, infection prevention and control healthcare products. The Company’s Dialysis segment includes medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates and other supplies for renal dialysis. The Company offers a range of filters utilizing hollow fiber membrane technology.